Prognostic Value of COX-2, NF-κB, and Sp1 Tissue Expressions in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis.
Journal
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
ISSN: 2148-5607
Titre abrégé: Turk J Gastroenterol
Pays: Turkey
ID NLM: 9515841
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
entrez:
7
12
2021
pubmed:
8
12
2021
medline:
19
2
2022
Statut:
ppublish
Résumé
Pancreatic ductal adenocarcinoma (PDAC) is deadly cancer with a poor prognosis. Molecular prognostic markers are needed to predict the patient's survival. The cyclooxygenase-2 enzyme (COX-2) and its 2 major transcription factors--nuclear factorkappa B (NF-κB) and specificity protein 1 (Sp1)--are activated during inflammation caused by neoplasia. Several studies have investigated the association between the COX-2, NF-κB, and Sp1 tissue expressions with the patient's overall survival. Therefore, we conducted this systematic review and meta-analysis to evaluate those studies. We searched for relevant articles from the MEDLINE database through June 2020. Studies were eligible if they included dichotomized tissue protein expression status and the overall survival as the outcome. We used RevMan and ProMeta programs to perform the meta-analysis. We identified 11 eligible studies. The meta-analysis showed that COX-2 tissue expression was associated with decreased overall survival (crude HR = 1.35; 95% CI, 1.05-1.74), although the result was not significant when controlling for other covariates. The NF-κB tissue expression was associated with decreased overall survival (crude HR = 2.18; 95% CI, 1.49-3.18), although it was not significant when controlling for other covariates. The Sp1 tissue expression showed significantly decreased overall survival even when adjusted with other covariates (aHR = 3.47; 95% CI, 1.52-7.94). The limitations included searching only for English publications and the substantial heterogeneity among the studies. COX-2, NF-κB, and Sp1 tissue expressions have the potential to be used as prognostic markers in PDAC. Further studies are still needed to clarify the associations.
Sections du résumé
BACKGROUND
Pancreatic ductal adenocarcinoma (PDAC) is deadly cancer with a poor prognosis. Molecular prognostic markers are needed to predict the patient's survival. The cyclooxygenase-2 enzyme (COX-2) and its 2 major transcription factors--nuclear factorkappa B (NF-κB) and specificity protein 1 (Sp1)--are activated during inflammation caused by neoplasia. Several studies have investigated the association between the COX-2, NF-κB, and Sp1 tissue expressions with the patient's overall survival. Therefore, we conducted this systematic review and meta-analysis to evaluate those studies.
METHODS
We searched for relevant articles from the MEDLINE database through June 2020. Studies were eligible if they included dichotomized tissue protein expression status and the overall survival as the outcome. We used RevMan and ProMeta programs to perform the meta-analysis.
RESULTS
We identified 11 eligible studies. The meta-analysis showed that COX-2 tissue expression was associated with decreased overall survival (crude HR = 1.35; 95% CI, 1.05-1.74), although the result was not significant when controlling for other covariates. The NF-κB tissue expression was associated with decreased overall survival (crude HR = 2.18; 95% CI, 1.49-3.18), although it was not significant when controlling for other covariates. The Sp1 tissue expression showed significantly decreased overall survival even when adjusted with other covariates (aHR = 3.47; 95% CI, 1.52-7.94). The limitations included searching only for English publications and the substantial heterogeneity among the studies.
CONCLUSION
COX-2, NF-κB, and Sp1 tissue expressions have the potential to be used as prognostic markers in PDAC. Further studies are still needed to clarify the associations.
Identifiants
pubmed: 34872897
doi: 10.5152/tjg.2021.211106
pmc: PMC8975516
doi:
Substances chimiques
Biomarkers, Tumor
0
NF-kappa B
0
Sp1 Transcription Factor
0
SP1 protein, human
0
Cyclooxygenase 2
EC 1.14.99.1
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
956-970Références
Br J Cancer. 2007 Aug 20;97(4):523-30
pubmed: 17622249
Int J Med Sci. 2020 Apr 27;17(8):1095-1101
pubmed: 32410839
Trials. 2007 Jun 07;8:16
pubmed: 17555582
Sci Rep. 2017 Mar 28;7(1):470
pubmed: 28352075
Int J Cell Biol. 2012;2012:723419
pubmed: 22505934
J Clin Pathol. 2006 Apr;59(4):382-6
pubmed: 16467169
Cancer Lett. 2018 May 1;421:127-134
pubmed: 29432846
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Front Oncol. 2021 Jan 14;10:621937
pubmed: 33520728
Prog Lipid Res. 2007 Mar;46(2):108-25
pubmed: 17316818
Curr Med Chem. 2012;19(22):3779-86
pubmed: 22725697
Oncotarget. 2016 May 10;7(19):28207-17
pubmed: 27057636
JOP. 2008 Mar 08;9(2):99-132
pubmed: 18326920
BMC Cancer. 2014 Jun 20;14:458
pubmed: 24950702
Nat Rev Immunol. 2005 Oct;5(10):749-59
pubmed: 16175180
BMJ. 2019 Jan 30;364:k4597
pubmed: 30700442
Br J Cancer. 2005 Jun 20;92(12):2225-32
pubmed: 15928668
Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1648-52
pubmed: 18628415
J Cell Physiol. 2001 Aug;188(2):143-60
pubmed: 11424081
Respir Med. 2004 Feb;98(2):164-72
pubmed: 14971881
Oncol Lett. 2019 Jun;17(6):5361-5368
pubmed: 31186753
Cancer Res. 2002 Mar 15;62(6):1676-81
pubmed: 11912139
PLoS One. 2018 May 29;13(5):e0198223
pubmed: 29813121
Mol Cancer. 2005 Aug 05;4:27
pubmed: 16083499
Oncology. 2013;85(2):86-94
pubmed: 23860225
FEBS J. 2015 Jan;282(2):224-58
pubmed: 25393971
Am J Clin Pathol. 2002 Aug;118(2):194-201
pubmed: 12162677
J Cell Physiol. 2019 May;234(5):5683-5699
pubmed: 30341914
Cancer Biol Ther. 2007 Oct;6(10):1569-75
pubmed: 18000398
Lancet. 2011 Aug 13;378(9791):607-20
pubmed: 21620466
Pancreatology. 2005;5(4-5):361-9
pubmed: 15980665
Pancreas. 2013 Oct;42(7):1114-9
pubmed: 24005232
Tumour Biol. 2018 Jan;40(1):1010428317750929
pubmed: 29345201
Oncotarget. 2014 Nov 30;5(22):10969-75
pubmed: 25473891
Oncotarget. 2016 Nov 29;7(48):78557-78565
pubmed: 27713167
World J Gastroenterol. 2014 Aug 21;20(31):10729-39
pubmed: 25152576
PLoS Med. 2012;9(5):e1001216
pubmed: 22675273
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Clin Cancer Res. 2011 May 15;17(10):3316-31
pubmed: 21444679
Tumour Biol. 2014 Oct;35(10):10301-7
pubmed: 25034525